Drugs

, Volume 31, Issue 4, pp 301–336 | Cite as

Guanfacine

A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy in the Treatment of Hypertension
  • Eugene M. Sorkin
  • Rennie C. Heel
Drug Evalution

Summary

Synopsis: Guanfacine,1 a phenylacetyl-guanidine derivative, is a centrally acting α-adrenoceptor agonist, with a mechanism of antihypertensive action similar to that of clonidine. It reduces blood pressure in patients with essential hypertension at least as effectively as clonidine or methyldopa. Like lower doses of clonidine, guanfacine can be given once daily due to its relatively long elimination half-life. Although dry mouth and sedation occur frequently with higher doses of guanfacine, their incidence is lower than with other centrally acting antihypertensives; in addition, other troublesome side effects such as orthostatic hypotension or sexual dysfunction also occur much less with guanfacine than with other centrally acting antihypertensive agents. While a withdrawal syndrome may occur on abruptly discontinuing guanfacine administration, the symptoms are generally mild, and the incidence of withdrawal symptoms appears lower than occurs with abrupt withdrawal of clonidine.

Thus, guanfacine is an effective and well tolerated alternative to other centrally acting antihypertensive drugs. Whether its final place in therapy will be as an alternative ‘second-line’ drug, or as initial monotherapy in patients with mild to moderate hypertension, remains to be clarified in comparative studies with diuretics, calcium antagonists, and β-adrenoceptor blocking drugs.

Pharmacodynamic Properties: Guanfacine is an α-adrenoceptor agonist which decreases central sympathetic tone. This has been substantiated in several animal models where intravertebral arterial and intracerebroventricular injection of guanfacine produced blood pressure reductions (not seen with intravenous administration) which were blocked by prior central injections of phentolamine. In addition, guanfacine causes a reduction of central sympathetic outflow and decreases the electrical activity of preganglionic sympathetic nerves, as well as reducing noradrenaline (norepinephrine) turnover in the brain.

The selectivity of guanfacine for α2-adrenoceptors has been verified by radioligand binding studies in which guanfacine was shown preferentially to bind cerebral cortex α2-adrenoceptor sites with essentially no activity on dopamine-, serotonin-, histamine H1-or β-adrenoreceptor sites. Guanfacine may be as much as 12 times more specific than clonidine for the α2 than the α1adrenoceptor.

Guanfacine also activates peripheral α-adrenoceptors, as transient increases in blood pressure produced by its intravenous administration in animal models of hypertension are not seen after intracisternal administration, and are prevented by the administration of phentolamine. Similarly, in man guanfacine has decreased blood pressure and plasma noradrenaline concentrations while causing subsequent increases in growth hormone concentrations, also indicating that guanfacine reduces sympathetic activity through both central and peripheral actions. Thus, the overall effect of guanfacine on mean arterial pressure is the summation of opposing pre- and postsynaptic peripheral and central effects, with the central effects rapidly predominating.

Guanfacine has been reported to decrease supine systolic and diastolic blood pressure in patients with mild to moderate essential hypertension by up to 24%, and standing systolic and diastolic blood pressures by up to 37%. Maximum blood pressure reduction occurs 8 to 12 hours after oral administration and this reduction is maintained for up to 36 hours after discontinuation of the drug. Although guanfacine is 5 to 20 times less potent than clonidine on a weight basis, comparable blood pressure lowering effects have been achieved when the 2 drugs were given in appropriate equipotent dosages. However, the onset of guanfacine action appears to be slower and its duration of action may tend to be longer than that of clonidine.

The primary effect of guanfacine on cardiovascular haemodynamics that contributes to its effectiveness as an antihypertensive agent is its ability to reduce systemic vascular resistance. Oral administration for up to 12 weeks has produced significant reductions of up to 20% and 15%, respectively, in rest and exercise systemic vascular resistance values. These reductions of left ventricular impedance (afterload) have resulted in concomitant improvements in left ventricular performance, which would be desirable in patients with incipient cardiac failure.

Dose-related reductions in plasma renin activity occur after administration of guanfacine, with plasma renin activity gradually returning to pretreatment levels within 4 days of guanfacine withdrawal. However, reductions in blood pressure produced by guanfacine are related neither to simultaneous reductions in plasma renin activity nor to pretreatment basal plasma renin activity levels.

Pharmacokinetic Properties: Orally administered guanfacine is rapidly and completely absorbed, with peak plasma concentrations occurring 1 to 4 hours after administration. Dose-related steady-state plasma concentrations are reached within 4 days of the initiation of guanfacine therapy. Guanfacine is widely distributed, with volumes of distribution ranging from 276 to 456L in healthy subjects and in hypertensive patients. Thus, low guanfacine plasma concentrations are achieved in spite of the high bioavailability of the drug. The total clearance of guanfacine from human plasma is between 11 and 22 L/h, and the drug is primarily metabolised by the liver; 24 to 37% is excreted unchanged by the kidneys. Neither maintenance doses nor dosage intervals of guanfacine need to be modified in patients with renal failure or in those undergoing intermittent haemodialysis.

Therapeutic Trials: Open studies of guanfacine in the treatment of mild-to-moderate hypertension have shown it to decrease blood pressure by 13 to 18% in most patients. However, two long term (3 and 5 years, respectively) studies reported that guanfacine decreased blood pressures by up to 19 to 29%. Guanfacine has been used as effective monotherapy in the treatment of patients with mild-to-moderate hypertension and in cases where previous antihypertensive therapy has been ineffective. During long term treatment with guanfacine there was no need for increased doses to maintain antihypertensive effectiveness in most patients. Indeed, the addition of diuretics or other anti-hypertensives to the guanfacine treatment regimen may prevent the apparent tolerance that has been reported in some patients and in fact allow the guanfacine dosage to be reduced. Normalisation of blood pressures has been shown to be greatest, with fewer associated side effects, when guanfacine has been given once daily; twice daily or 3 times daily dosages not only produced lower normalisation rates, but also increased the incidence of side effects.

Placebo-controlled studies have likewise shown guanfacine to produce significant blood pressure lowering effects, which were apparent within about 7 days after the initiation of therapy.

Although there have been few well-controlled clinical trials comparing the antihypertensive effectiveness of guanfacine and diuretics, either alone or in combination, considerable increases in antihypertensive efficacy have been reported when diuretics have been added to guanfacine therapy, and vice versa.

Several controlled clinical trials have shown that guanfacine produces antihypertensive effects comparable with those produced by clonidine and many investigators have reported that guanfacine and methyldopa also produce equivalent blood pressure lowereng effects. However, some studies have shown that guanfacine has been slightly more effective than methyldopa in decreasing blood pressure.

While there have been very few studies investigating the comparative and/or additive effects of guanfacine with other centrally acting antihypertensives, vasodilators or β-blockers, both guanfacine and guanabenz have been noted to produce equivalent blood pressure lowering effects. Furthermore, the addition of hydralazine or endralazine to treatment regimens of guanfacine has produced greater blood pressure reductions than guanfacine monotherapy, suggesting that guanfacine may also be used as an alternative to β-blockers to counteract increases in sympathetic nervous tone that are induced by arterial vasodilators. Both guanfacine and pindolol have been used in combination with diuretics and have resulted in equivalent blood pressure reductions, and the addition of propranolol to guanfacine/diuretic therapy has produced greater antihypertensive effects than the prior 2-drug combination. However, further studies comparing guanfacine with vasodilators and β-blockers are needed.

Side Effects: Side effects due to guanfacine are generally dependent on dose and dose frequency, and usually occur during the beginning of treatment with the drug, especially when large doses are given or when the dosage is increased or other drugs are added to the treatment regimen. As with other centrally acting antihypertensive drugs, the most common side effects of guanfacine are dry mouth and sedation, which have been reported to occur in 60% and 33% of patients, respectively, who have been treated over a period of 1 year. However, the incidence of such effects, and others such as headache, impotence and orthostatic hypotension, appears to be lower with guanfacine than with clonidine or guanethidine.

Withdrawal of Guanfacine: Severe rebound hypertension or marked withdrawal syndromes are rarely seen after discontinuation of guanfacine therapy. When a withdrawal syndrome associated with guanfacine use has been noted, its onset was slower, and symptoms less severe, than the syndrome following abrupt withdrawal of clonidine. Predisposing factors favouring the occurrence of a withdrawal syndrome include patients with histories of very high blood pressure, tachycardia, prior antihypertensive drug therapy, and those receiving divided doses of guanfacine exceeding 4mg per day.

Dosage and Administration: Oral antihypertensive therapy with guanfacine should be initiated with 0.5mg to 1.0mg per day, given once daily at bedtime. If necessary, dosage increases of 0.5mg or 1.0mg may be made after intervals of no less than 1 or 2 weeks. If the desired reduction in blood pressure is not achieved with 2 or 3mg daily given as a single dose, a diuretic may be added in the smallest recommended dose. Conversely, if guanfacine is to be added to the therapeutic regimen of a patient already receiving a diuretic, 1mg given once daily at bedtime will usually suffice in further decreasing blood pressure. Additional increases in guanfacine dosage up to a maximum of 2 to 3 mg/day may also be made in similar increments as described above.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andén, N-E, Grabowska M, Strömbom U. Different alpha-adrenoceptors in the central nervous system mediating biochemical and functional effects of clonidine and receptor blocking agents. Naunyn-Schmiedeberg’s Archives of Pharmacology 292: 43–52, 1976PubMedGoogle Scholar
  2. Barber ND, Reid JL. Studies on clonidine and guanfacine withdrawal after short term treatment in the rat. Archives Internationales de Pharmacodynamie et de Thérapie 259: 112–118, 1982PubMedGoogle Scholar
  3. Barber ND, Reid JL. Comparisons of the actions of centrally and peripherally administered clonidine and guanfacine in the rabbit: investigation of the differences. British Journal of Pharmacology 77: 641–647, 1982PubMedGoogle Scholar
  4. Barber ND, Zamboulis C, Reid JL. Comparison of cardiovascular and other effects of clonidine and BS 100-141. In Boissier JR, Lechat P (Eds) 7th Congress of International Pharmacology, Paris, July 16–21, 1978. Abstract no. 2715p. 879, Pergamon Press, Oxford-Paris, 1978Google Scholar
  5. Bayliss PFC, Duncan SM. The effects of atenolol (Tenormin) and methyldopa on simple tests of central nervous function. British Journal of Clinical Pharmacology 2: 527–531, 1975PubMedGoogle Scholar
  6. Beevers DG, Bloxham CA, Walker JM. Guanfacine: a new centrally-acting antihypertensive agent. Pharmatherapeutica 2: 513–516, 1981PubMedGoogle Scholar
  7. Benet LZ, Sheiner LB. Design and optimization of dosage regimens; pharmacokinetic data. In Gilman AG, Goodman LS, Gilman A (Eds) The Pharmacological Basis of Therapeutics, 6th ed., pp. 1675–1737, Macmillan, New York, 1980Google Scholar
  8. Bock JU, van Zwieten PA. The central hyperglycaemic effect of clonidine. European Journal of Pharmacology 16: 303–310, 1971PubMedGoogle Scholar
  9. Brodde O-E, Hardung A, Ebel H, Bock KD. GTP regulates binding of agonists to α2-adrenergic receptors in human platelets. Archives Internationales de Pharmacodynamie et de Thérapie 258: 193–207, 1982PubMedGoogle Scholar
  10. Brogden RN, Pinder RM, Sawyer PR, Speight TM, Avery GS. Low-dose clonidine: a review of its therapeutic efficacy in migraine prophylaxis. Drugs 10: 357–365, 1975PubMedGoogle Scholar
  11. Brown MJ, Harland D, Murphy MB, Struthers AD. Effect of centrally acting α-adrenergic agonists on sympathetic nervous system function in humans. Hypertension 6 (Suppl. II): 57–62, 1984Google Scholar
  12. Brown MJ, Struthers AD. Guanfacine lowers plasma noradrenaline by peripheral α2-adrenoceptor stimulation in man. British Journal of Clinical Pharmacology 19: 534P-535P, 1985Google Scholar
  13. Brown MJ, Struthers AD, di Silvio L. Peripheral α2-adrenoceptor stimulation contributes to the sympatholytic effect of guanfacine in humans. Journal of Cardiovascular Pharmacology 7 (Suppl. 6): S159–S161, 1985PubMedGoogle Scholar
  14. Bune AJ, Chalmers JP, Graham JR, Howe PRC, West MJ, et al. Double-blind trial comparing guanfacine and methyldopa in patients with essential hypertension. European Journal of Clinical Pharmacology 19: 309–315, 1981PubMedGoogle Scholar
  15. Carchman SH, Crowe JT, Wright GJ. Steady-state plasma levels and pharmacokinetics of guanfacine in hypertensive patients with normal renal function. Clinical Pharmacology and Therapeutics 37: 186, 1985Google Scholar
  16. Carette B, Thomas M, Deschildre A, Ostermann G, Bajolet A. Étude clinique de la guanfacine dans le traitement de l’hypertension artérielle. L’Information Cardiologique 5: 975–978, 1981Google Scholar
  17. Casado MJ, Canto J, Yapur H, Oller JM. Ensayo ‘doble ciego’ de un nuevo hipotensor de acción central, guanfacina, frente a alfa-metildopa. Revista Clinica Espanola 174: 41–44, 1984Google Scholar
  18. Chierichetti SM, Fiorella G, Vibelli, C, Capitani M, Nami R, et al. Double-blind comparison between acute guanfacine and clonidine administrations on hypotensive activity and side effects in healthy volunteers and hypertensive patients. Current Therapeutic Research 31: 588–600, 1982Google Scholar
  19. Clayton AB, Harvey PG, Betts TA. The psychomotor effects of atenolol and other antihypertensive agents. Postgraduate Medical Journal 53 (Suppl.): 157–161, 1977PubMedGoogle Scholar
  20. Collart F, Staroukine M, Verniory A. Relationships between blood pressure, heart rate and plasma epinephrine, norepinephrine, angiotensin II concentrations, plasma renin activity during chronic guanfacine therapy in patients with essential arterial hypertension. Acta Cardiologica 40: 269–276, 1985PubMedGoogle Scholar
  21. Dausse J-P, Cardot A, Meyer P. Specific binding of 3H-guanfacine to α2-adrenoceptors in rat brain. Journal de Pharmacologie 14: 35–46, 1983PubMedGoogle Scholar
  22. DeLuca I, Lettini A, Castellaneta G, Calcagno F, Colonna L. La guanfacina nell’ipertensione: studio clinico controllato in confronto ad alfa-metildopa. Medica Praxis 2: 39–46, 1981Google Scholar
  23. Distler A, Kirch W, Lüth B. Antihypertensive effect of guanfacine: a double-blind cross-over trial compared with clonidine. British Journal of Clinical Pharmacology 10 (Suppl. 1): 49–53, 1980Google Scholar
  24. Dollery CT, Davies DS. Centrally acting drugs in antihypertensive therapy. British Journal of Clinical Pharmacology 10 (Suppl. 1): 5–12, 1980Google Scholar
  25. Dubach UC, Huwyler R, Radielovic P, Singeisen M. A new centrally acting antihypertensive agent guanfacine (BS 100-141). Arzneimittel-Forschung 27: 674–676, 1977PubMedGoogle Scholar
  26. Dupont AG, Vanderniepen P, Six RO. Guanfacine in elderly hypertensive patients: effect on ambulatory blood pressure and its variability. Ric. Scientific. Educ. Perm. (Univ. Milano) Suppl. 49: abstract No. 149, 1985Google Scholar
  27. Efstratopoulos AD, Spantideas A, Sakopoulou-Pipi H, Andrianakos A, Yotis A, et al. Treatment of arterial hypertension. Trial of a new antihypertensive, guanfacine (Estulic). Clinical Trials Journal 19: 129–136, 1982Google Scholar
  28. Engel G, Hoyer D. [125I] BE 2254, a new high affinity radioligand for α1adrenoceptors. European Journal of Pharmacology 73: 221–224, 1981PubMedGoogle Scholar
  29. Farooki MS. Guanfacine: single daily dose in the treatment of mild to moderate hypertension (abstract). Clinical and Investigative Medicine 5: 1B, 1982Google Scholar
  30. Farooki MS, Farsky K, Bouchard S, Lalonde Y, Brookman S. Comparison of once-daily guanfacine and twice-a-day methyldopa in the treatment of mild to moderate hypertension. Clinical Therapeutics 7: 199–204, 1985PubMedGoogle Scholar
  31. Farsang C, Varga K, Vajda L, Alföldi S, Kapocsi J. Effects of clonidine and guanfacine in essential hypertension. Clinical Pharmacology and Therapeutics 36: 588–594, 1984PubMedGoogle Scholar
  32. Feldstein CA, Cohen AA, Sabaris RP, Burucúa JE. Hemodynamic effects of guanfacine in essential hypertension. Clinical Therapeutics 6: 325–334, 1984PubMedGoogle Scholar
  33. Fillingim JM. Guanfacine as monotherapy. American Journal of Cardiology 57: in press, 1986Google Scholar
  34. Geyskes GG, Boer P, Dorhout Mees EJ. Clonidine withdrawal. Mechanism and frequency of rebound hypertension. British Journal of Clinical Pharmacology 7: 55–62, 1979Google Scholar
  35. Glusa E, Markwardt F. Characterisation of postjunctional α-adrenoceptors in isolated human femoral veins and arteries. Naunyn-Schmiedeberg’s Archives of Pharmacology 323: 101–105, 1983PubMedGoogle Scholar
  36. Goldberg AD, Raftery EB, Wilkinson P. Blood pressure and heart rate and withdrawal of antihypertensive drugs. British Medical Journal 1: 1243–1246, 1977PubMedGoogle Scholar
  37. Goldberg AD, Wilkinson PR, Raftery EB. The overshoot phenomenon on withdrawal of clonidine therapy. Postgraduate Medical Journal 52 (Suppl. 7): 128–134, 1976PubMedGoogle Scholar
  38. Guerret M, Julien-Larose C, Kiechel JR, Lavène D. Determination of 3-hydroxy-guanfacine in biological fluids by electron-capture gas-liquid chromatography. Journal of Chromatography 233: 181–192, 1982PubMedGoogle Scholar
  39. Guerret M, Lavéne D, Longchampt J, Kiger JL. Determination of guanfacine in biological fluids by electron-capture GLC. Journal of Pharmaceutical Sciences 68: 219–221, 1979PubMedGoogle Scholar
  40. Hansson L. Clinical aspects of blood pressure crisis due to withdrawal of centrally acting antihypertensive drugs. British Journal of Clinical Pharmacology 15 (Suppl. 4): 485–489, 1983Google Scholar
  41. Hansson L, Hunyor SN, Julius S, Hoobler SW. Blood pressure crisis following withdrawal of clonidine (Catapres, Catapresan), with special reference to arterial and urinary catecholamine levels and suggestions for acute management. American Heart Journal 85: 605–610, 1973PubMedGoogle Scholar
  42. Hauger-Klevene JH. Active and inactive renin and prolactin in essential hypertension: effect of pindolol alone or in combination with clopamide and BS-100/141. In Velasco M (Ed.) Proceedings of the International Symposium of Arterial Hypertension, pp. 129–136, Excerpta Medica, Amsterdam, 1979Google Scholar
  43. Hauger-Klevene JH. Treatment of drug-resistant severe essential hypertension with the combination of guanfacine and BQ-22-708: effect on plasma renin activity levels. Drugs Under Experimental and Clinical Research 8: 335–343, 1982Google Scholar
  44. Hauger-Klevene JH. Efecto de la guanfacina en la presion arterial y glucemia en la hipertension arterial esencial. Semana Medica 163: 399–403, 1983Google Scholar
  45. Hauger-Klevene JH. Guanfacine-induced withdrawal syndrome: effect of labetalol. Drugs Under Experimental and Clinical Research 12:911–916, 1983Google Scholar
  46. Hauger-Klevene JH. Hypolipaemic effect of guanfacine: two years’ follow-up. Drugs Under Experimental and Clinical Research 10: 133–140, 1984Google Scholar
  47. Hauger-Klevene JH, Balossi EC, Scornavacchi JC. The effects of guanfacine on growth hormone, prolactin, renin, lipoproteins and glucose in essential hypertension. American Journal of Cardiology 57: in press, 1986Google Scholar
  48. Hauger-Klevene JH, Pinkas MB. Long-term treatment of essential hypertension with guanfacine: effect on cardiovascular complications, renin and prolactin. Current Medical Research and Opinion 7: 569–579, 1982Google Scholar
  49. Hauger-Klevene JH, Pinkas MB, Gerber S. Blood pressure and prolactin: effects of guanfacine. Three-year follow-up study. Hypertension 3 (Suppl. II): 222–225, 1981Google Scholar
  50. Hauger-Klevene JH, Scornavacchi JC. Improvement of glucose tolerance in hypertensive diabetic patients treated with guanfacine one year. European Journal of Clinical Pharmacology 29: 391–393, 1985PubMedGoogle Scholar
  51. Hedner T, Nyberg G, Mellstrand T. Guanfacine in essential hypertension: effects during rest and isometric exercise. Clinical Pharmacology and Therapeutics 35: 604–609, 1984PubMedGoogle Scholar
  52. Heidbreder E, Pagel G, Roeckel A, Heidland A. Effect of guanfacine on vigilance. British Journal of Clinical Pharmacology 10 (Suppl. 1): 169–172, 1980Google Scholar
  53. Higuchi M, Overlack A, Stumpe KO. Evaluation of long-term treatment of essential hypertension with guanfacine. British Journal of Clinical Pharmacology 10 (Suppl. 1): 61–64, 1980Google Scholar
  54. Hitzenberger G, Stumpe KO. Treatment of essential hypertension with a combination of a potent peripheral vasodilator (endralazine) with a central alpha-adrenoceptor stimulant (guanfacine). 8th European Congress of Cardiology, Paris, June 22–26, 1980. Abstract no. 1120, p. 88, 1980Google Scholar
  55. Hulley SB, Rosenmann R, Bowel R. High density lipoproteins and atherosclerosis. Annual Review of Medicine 31: 97–104, 1980Google Scholar
  56. Hökfelt B, Hedeland H, Dymling JF. Studies on catecholamines, renin and aldosterone following catapresan in hypertensive patients. European Journal of Pharmacology 10: 389–397, 1970PubMedGoogle Scholar
  57. Irmer M, Just H. Acute and longterm haemodynamic effects of guanfacine. European Heart Journal 2 (Suppl. A): 59, 1981Google Scholar
  58. Jäättelä A. Comparison of BS 100-141 and clonidine as antihypertensive agents. European Journal of Clinical Pharmacology 10: 73–76, 1976Google Scholar
  59. Jäättelä A. Clinical efficacy of BS 100-141 in essential hypertension. A single-blind pilot study. European Journal of Clinical Pharmacology 10: 69–72, 1976Google Scholar
  60. Jain AK, Hiremath A, Michael R, Ryan JR, McMahon FG. Clonidine and guanfacine in hypertension. Clinical Pharmacology and Therapeutics 37: 271–276, 1985PubMedGoogle Scholar
  61. Jarrott B. Clonidine and related compounds. In Doyle AE (Ed.) Handbook of hypertension, Vol. 5, Clinical pharmacology of antihypertensive drugs, pp. 113–168, Elsevier Science Publishers, Amsterdam, 1984Google Scholar
  62. Jarrott B, Louis WJ, Summers RJ. [3H]-Guanfacine: a radioligand that selectively labels high affinity α2-adrenoceptor sites in homogenates of rat brain. British Journal of Pharmacology 75: 401–408, 1982PubMedGoogle Scholar
  63. Jerie P. Clinical experience with guanfacine in long-term treatment of hypertension. Part I: efficacy and dosage. British Journal of Clinical Pharmacology 10 (Suppl. 1): 37–47, 1980Google Scholar
  64. Jerie P. Clinical experience with guanfacine in long-term treatment of hypertension. Part II: adverse reactions to guanfacine. British Journal of Clinical Pharmacology 10 (Suppl. 1): 157–164, 1980Google Scholar
  65. Jerie P. Low, single daily doses of guanfacine in the ambulatory treatment of hypertension. British Journal of Clinical Pharmacology 15 (Suppl. 4): 479–483, 1983Google Scholar
  66. Jerie P, Lasance A. Guanfacine in the treatment of hypertension: two years’ experience with low dose monotherapy. International Journal of Clinical Pharmacology, Therapy and Toxicology 19: 279–287, 1981Google Scholar
  67. Jerie P, Lasance A. Long-term efficacy and tolerance of the anti-hypertensive agent guanfacine. International Journal of Clinical Pharmacology, Therapy and Toxicology 22: 170–174, 1984Google Scholar
  68. Joshi RC, De A, Cameron EGM. A comparative study of a new alpha-adrenoceptor agonist, guanfacine and alpha-methyldopa in the treatment of hypertension. British Journal of Clinical Practice 38: 66–71, 1984PubMedGoogle Scholar
  69. Kállay K, Szám I, Káldi N. Guanfacin és guanethidin vérnyomascsökkentö hatásának összehasonlitó vizsgálata. Orvosi Hetilap 122: 1777–1779, 1981PubMedGoogle Scholar
  70. Kamimura S, Okuda M, Kitahara N, Totori T, Tanaka Y, et al. Metabolic studies on N-amidino-2-(2,6-dichlorophenyl)-acetamide hydrochloride (guanfacine), a new antihypertensive agent. (1) Absorption, distribution and excretion in rats after single and repeated oral administration. Pharmacometrics 20: 741–744, 1980Google Scholar
  71. Kamimura S, Okuda M, Totori T, Kitahara N, Tanaka Y, et al. Metabolic studies on N-amidino-2-(2,6-dichlorophenyl)-acetamide hydrochloride (guanfacine), a new antihypertensive agent. (3) Placental transfer and metabolites in fetus of rats. Pharmacometrics 20: 753–755, 1980Google Scholar
  72. Keenan RE. The 24-hour duration of hypertension control with guanfacine. American Journal of Cardiology 57: in press, 1986Google Scholar
  73. Kiechel JR. Pharmacokinetics and metabolism of guanfacine in man: a review. British Journal of Clinical Pharmacology 10 (Suppl. 1): 25–32, 1980Google Scholar
  74. Kiechel JR. Biotransformation of drugs during aging. Gerontology 28 (Suppl. 1): 101–112, 1982PubMedGoogle Scholar
  75. Kiechel JR, Lavène D, Guerret M, Comoy E, Godin M, et al. Pharmacokinetic aspects of guanfacine withdrawal syndrome in a hypertensive patient with chronic renal failure. European Journal of Clinical Pharmacology 25: 463–466, 1983PubMedGoogle Scholar
  76. Kiechel JR, Lavène D, Guerret M, Coustenoble J, Petrover M, et al. Pharmacokinetic study of guanfacine in renal insufficiency and hemodialysis. Nephrology 1: 73–81, 1980Google Scholar
  77. Kirch W, Distler A. Antihypertensive effect of N-amidino-2-(2,6-dichlorophenyl) acetamide hydrochloride: a double-blind crossover trial versusclonidine. International Journal of Clinical Pharmacology and Biopharmacy 16: 132–135, 1978PubMedGoogle Scholar
  78. Kirch W, Köhler H, Braun W. Elimination of guanfacine in patients with normal and impaired renal function. British Journal of Clinical Pharmacology 10 (Suppl. 1): 33–35, 1980Google Scholar
  79. Kirch W, Köhler H, Braun W, v. Gizycki Ch. The influence of renal function on plasma concentration, urinary excretion and antihypertensive effect of guanfacine. Clinical Pharmacokinetics 5: 476–483, 1980PubMedGoogle Scholar
  80. Kirch W, Köhler H, Axthelm T. Pharmacokinetics of guanfacine in patients undergoing hemodialysis. European Journal of Drug Metabolism and Pharmacokinetics 7: 277–280, 1982PubMedGoogle Scholar
  81. Kirch W, Ohnhaus EE. The elimination of guanfacine, a central acting antihypertensive agent, in normal and impaired renal function and in patients undergoing haemodialysis treatment. Naunyn-Schmiedeberg’s Archives of Pharmacology 322(Suppl.): R131, 1983Google Scholar
  82. Kleinlogel H, Scholtysik G, Sayers AC. Effects of clonidine and BS 100-141 on the sleep pattern of rats. European Journal of Pharmacology 33: 159–163, 1975PubMedGoogle Scholar
  83. Kobinger W, Pichler L. α12selectivity ratio in a series of agonists and their relation to pre/postsynaptic activity ratios. European Journal of Pharmacology 91: 129–133, 1983PubMedGoogle Scholar
  84. Koike Y, Togashi H, Shimamura K, Yomaida I, Saito H. Effects of abrupt cessation of treatment with clonidine and guanfacine on blood pressure and heart rate in spontaneously hypertensive rats. Clinical and Experimental Hypertension — Part A — Theory and Practice 3: 103–120, 1981Google Scholar
  85. Kugler J, Seus R, Krauskopf R, Brecht HM, Raschig A. Differences in psychic performance with guanfacine and clonidine in normotensive subjects. British Journal of Clinical Pharmacology 10 (Suppl. 1): 71–80, 1980Google Scholar
  86. Lancranjan I. Effect of guanfacine on pituitary hormones in man. British Journal of Clinical Pharmacology 10 (Suppl. 1): 151–156, 1980Google Scholar
  87. Lancranjan I, del Pozo E, Marbach P, Girard J. The effect of a new central a-adrenoceptor agonist on pituitary function in man. Acta Endocrinologica 85 (Suppl. 212): 80, 1977Google Scholar
  88. Lancranjan I, del Pozo E, Ohnhaus E. Inhibitory effect of guanfacine, a central α-adrenoceptor agonist, on prolactin secretion stimulated by insulin-induced hypoglycemia. Journal of Clinical Endocrinology and Metabolism 47: 671–674, 1978PubMedGoogle Scholar
  89. Lancranjan I, Marbach P. New evidence for growth hormone modulation by the a-adrenergic system in man. Metabolism 26: 1225–1230, 1977PubMedGoogle Scholar
  90. Laplanche R, Morin Y. Automated determination of Estulic® in biological fluids using a selected ion monitoring technique and an operator controlled data processing. In Leenheer D, Roncucci APRR (Eds) Quantitative Mass Spectrometry in Life Sciences II, pp. 339–345, Elsevier, Amsterdam, 1978Google Scholar
  91. Lauro R, Reda G, Spallone L, Beretta Anguissola A. Hypotensive effect of guanfacine in essential hypertension: a comparison with clonidine. British Journal of Clinical Pharmacology 10 (Suppl. 1): 81–82, 1980Google Scholar
  92. Lefkowitz RJ, Caron MG, Stiles GL. Mechanism of membrane-receptor regulation. Biochemical, physiological and clinical insights derived from studies of the adrenergic receptors. New England Journal of Medicine 310: 1570–1579, 1984Google Scholar
  93. Limone P, Cagliero E, Massara F, Molinatti GM. Reduced glucose tolerance after guanfacine in normal and obese subjects. Hormone and Metabolic Research 15: 352, 1983PubMedGoogle Scholar
  94. Lochaya S, Thongmitr V, Suvachittanont O. Antihypertensive effect of BS 100-141, a new central acting antihypertensive agent. American Heart Journal 99: 58–63, 1980PubMedGoogle Scholar
  95. Louis WJ, Summers RJ, Dynon M, Jarrott B. New developments in α-adrenoceptor drugs for the treatment of hypertension. Journal of Cardiovascular Pharmacology 4 (Suppl. 1): 168–171, 1982Google Scholar
  96. Lovinger R, Holland J, Kaplan S, Grumbach MM. Pharmacological evidence for stimulation of growth hormone secretion by a central noradrenergic system in dogs. Neuroscience 1: 443–450, 1976PubMedGoogle Scholar
  97. Magometschnigg D, Bonelli J, Gassner A, Hitzenberger G, Lenzhofer R, et al. Duration of the hypotensive effect of guanfacine. International Journal of Clinical Pharmacology, Therapy and Toxicology 20: 174–178, 1982Google Scholar
  98. Magometschnigg D, Hitzenberger G, Bonelli J. Haemodynamic effects of guanfacine. British Journal of Clinical Pharmacology 10 (Suppl. 1): 125–131, 1980Google Scholar
  99. Malini PL, Strocchi E, Ambrosioni E, Magnani B. Comparison of antihypertensive activity and tolerability of guanfacine and methyldopa. International Journal of Clinical Pharmacy Research 3: 35–39, 1983Google Scholar
  100. Manhem P, Hökfelt B. Blood pressure, heart rate, catecholamines and plasma renin activity following institution and withdrawal of guanfacine treatment in moderate hypertension. British Journal of Clinical Pharmacology 10 (Suppl. 1): 109–114, 1980Google Scholar
  101. Man in T Veld AJ, Boomsa F, Schalekamp MADH: Regulation of α- and α-adrenoceptor responsiveness. Studies in patients with chronic autonomic failure. British Journal of Clinical Pharmacology 15 (Suppl. 4): 507–519, 1983Google Scholar
  102. Materson BJ, Kessler WB, Alderman MH, Canosa FL, Finnerty FA, et al. A multi-center, randomized, double-blind dose-response evaluation of step-2 guanfacine versusplacebo in patients with mild-to-moderate hypertension. American Journal of Cardiology 57: in press, 1986Google Scholar
  103. McMahon FG (Ed.) Management of essential hypertension, Futura Publishing Company, Mount Kisco, New York, 1978Google Scholar
  104. Meier J, Beveridge T, Laplanche R, Kiechel JR, Ohnhaus EE. Pharmacokinetics of the hypotensive agent guanfacine in man. 8th World Congress of Cardiology, Tokyo, September 17–23, 1978. Abstract no. 1087, p. 362, 1978Google Scholar
  105. Meregalli M, Guffanti E, Fiorella G, Chierichietti SM, Mazzola C. Effects during and after treatment of hypertension with guanfacine: a controlled clinical trial in comparison with alpha-methyldopa. Current Therapeutic Research 34: 174–182, 1983Google Scholar
  106. Metz SA, Halter JB, Robertson RP. Induction of defective insulin secretion and impaired glucose tolerance by clonidine. Selective stimulation of metabolic alpha-adrenergic pathways. Diabetes 27: 554–562, 1978Google Scholar
  107. Murakami M, Ikeda M, Miyahara M. Clinical study of guanfacine (BS 100-141), a new centrally acting anti-hypertensive drug, in hypertensive patients. Phase II open study at 35 institutes. Rhinsho-to-Kenkyu 58: 243–260, 1981Google Scholar
  108. Murphy MB, Brown MJ. Peripheral α-receptor activation by ‘centrally acting’ drugs? Pharmacologist 25: 196, 1983Google Scholar
  109. Murphy MB, Brown MJ, Dollery CT. Evidence for a peripheral component in the sympatholytic actions of clonidine and guanfacine in man. European Journal of Clinical Pharmacology 27: 23–27, 1984PubMedGoogle Scholar
  110. Myhre E, Rugstad HE, Hansen T. Clinical pharmacokinetics of methyldopa. Clinical Pharmacokinetics 7: 221–233, 1982PubMedGoogle Scholar
  111. Nakagawa Y, Chin W, Imai S. Effects of guanfacine on pre- and postsynaptic α-adrenoceptors studied in comparison with those of clonidine. Folia Pharmacologica Japonica 79: 431–439, 1982PubMedGoogle Scholar
  112. Nami R, Bianchini C, Fiorella G, Chierichetti M, Gennari C. Comparison of effects of guanfacine and clonidine on blood pressure, heart rate, urinary catecholamines, and cyclic nucleotides during and after administration to patients with mild to moderate hypertension. Journal of Cardiovascular Pharmacology 5: 546–551, 1983PubMedGoogle Scholar
  113. Nukada T, Ashizawa H, Okada N, Ogiwara T, Okushio T, et al. Clinical effect of guanfacine, a centrally acting antihypertensive drug alone on essential hypertension. Double-blind inter-group comparative study with α-methyldopa as reference drug. Clinical Evaluation 10: 73–95, 1982Google Scholar
  114. Oates HF, Stoker LM, MacCarthy EP, Monaghan JC, Stokes GS. Comparative haemodynamic effects of clonidine and guanfacine. Archives Internationales de Pharmacodynamie et de Thérapie 231: 148–156, 1978PubMedGoogle Scholar
  115. Oates HF, Stoker LM, Stokes GS. Studies in the rat on the haemodynamic overshoot response to withdrawal of guanfacine or clonidine treatment. Clinical and Experimental Pharmacology and Physiology 6: 61–68, 1979PubMedGoogle Scholar
  116. Ollivier JP, Lecoq JP, Pauna B. Essai pragmatique d’un nouvel anti-hypertenseur: la guanfacine. Médecine Actuelle 8: 264–266, 1981Google Scholar
  117. Pagani G, Fiorella G, Benco R, Parodi D, Pagani MD, et al. Comparison of the effects of short-term treatment with guanfacine and clonidine on glucose metabolism, plasma renin activity and some anterior pituitary hormones. Current Therapeutic Research 36: 155–162, 1984Google Scholar
  118. Perez Olea J, Ortiz N, Bertolo MS, Allel L, Goity C, et al. Dosis minima util de guanfacina en hipertensos esenciales. Revista Medica de Chile 113: 420–424, 1985PubMedGoogle Scholar
  119. Philipp E. Guanfacine in the treatment of hypertension due to pre-eclamptic toxaemia in thirty women. British Journal of Clinical Pharmacology 10 (Suppl. 1): 137–140, 1980Google Scholar
  120. Picard CW, Bream JB. Guanfacine (BS 100-141) and related centrally acting α-adrenoceptor stimulants. Chemistry and structure-activity relationships. In Simkins MA (Ed.) Medicinal Chemistry VI, Proceedings of the 6th International Symposium on Medicinal Chemistry, pp. 45–59, Cotswold Press Limited, Oxford, 1979Google Scholar
  121. Putzeys MR, Hoobler SW. Comparison of clonidine and methyldopa on blood pressure and side effects in hypertensive patients. American Heart Journal 83: 464–468, 1972PubMedGoogle Scholar
  122. Reid JL, Rubin PC, Howden CW. Central α2-adrenoceptors and blood pressure regulation in man: studies with guanfacine (BS 100-141) and azepexole (BHT 933). British Journal of Clinical Pharmacology 15 (Suppl. 4): 463–469, 1983Google Scholar
  123. Reid JL, Wing LMH, Dargie HJ, Hamilton CA, Davies DS, et al. Clonidine withdrawal in hypertension: changes in blood pressure and plasma and urinary noradrenaline. Lancet 1:1 1174, 1977Google Scholar
  124. Reid JL, Zamboulis C, Hamilton CA. Guanfacine: effects of long-term treatment and withdrawal. British Journal of Clinical Pharmacology 10 (Suppl. 1): 183–188, 1980Google Scholar
  125. Rengo F, Ricciardelli B, Volpe M, Trimarco B, Sacca L, et al. Long term comparative study of guanfacine and alpha-methyldopa in essential hypertension. Archives Internationales de Pharmacodynamie et de Therapie 244: 281–291, 1980PubMedGoogle Scholar
  126. Roeckel A, Heidland A. Comparative studies of guanfacine and methyldopa. British Journal of Clinical Pharmacology 10 (Suppl. 1): 55–59, 1980Google Scholar
  127. Roman O, Valenzuela MA, Salazar R. Guanfacina en hipertension arterial primaria: estudio clinico abierto a largo plazo. Revista Médica de Chile 110: 1179–1184, 1982PubMedGoogle Scholar
  128. Rosenthal J. Effect of guanfacine on blood pressure and renin activity in hypertensive patients. British Journal of Clinical Pharmacology 10 (Suppl. 1): 91–96, 1980Google Scholar
  129. Rosenthal JH. Hemodynamic and endocrine responses to guanfacine in normotensive volunteers and hypertensive patients. American Journal of Cardiology 57: in press, 1986Google Scholar
  130. Rosenthal J, Schäfer N, Rauh J, Raschig A. Hämodynamische Untersuchungen mit dem neuen Antihypertensivum Guanfacin. Deutsche Medizinische Wochenschrift 105: 1680–1684,1980PubMedGoogle Scholar
  131. Saameli K, Scholtysik G, Waite R. Pharmacology of BS 100-141, a centrally acting antihypertensive drug. Clinical and Experimental Pharmacology and Physiology 2 (Suppl. 2): 207–212, 1975PubMedGoogle Scholar
  132. Safar M, Weiss Y, Georges D. Pharmacologie clinique de l’action antihypertensive de la guanfacine. Archives des Maladies du Coeur et des Vaisseaux 73: 1171–1177, 1980PubMedGoogle Scholar
  133. Sailer S, Lisch H-J, Patsch W. Guanfacine and glucose metabolism. British Journal of Clinical Pharmacology 10 (Suppl. 1): 123–124, 1980Google Scholar
  134. Schäfer N, Knaup G. Antihypertensive Therapie mit Guanfacin. Eine Multizenter-Studie mit Estulic®-Wander lmg. Münchener Medizinische Wochenschrift 124: 249–252, 1982Google Scholar
  135. Schäfer N, Rauh J, Rosenthal J. Haemodynamics in hypertensive patients before and during guanfacine treatment. British Journal of Clinical Pharmacology 10 (Suppl. 1): 133–135, 1980Google Scholar
  136. Schmitt H, Schmitt H, Boissier JR, Guidicelli JF. Centrally mediated decrease in sympathetic tone induced by 2(2,6-dichlorophenylamino)-2 Imidazoline (ST 155, Catapresan). European Journal of Pharmacology 2: 147–148, 1967PubMedGoogle Scholar
  137. Schoeppe W, Brecht HM. Guanfacine in essential hypertension: effect on blood pressure, plasma noradrenaline concentration and plasma renin activity. British Journal of Clinical Pharmacology 10 (Suppl. 1): 97–101, 1980Google Scholar
  138. Scholtysik G, Jerie P, Picard CW. Guanfacine. In Scriabine A (Ed.) Pharmacology of antihypertensive drugs, pp. 79–98, Raven Press, New York, 1980Google Scholar
  139. Scholtysik G, Lauener H, Eichenberger E, Biirki H, Salzmann R, et al. Pharmacological actions of the antihypertensive agent N-amidino-2-(2,6-dichlorophenyl) acetamide hydrochloride (BS 100-141). Arzneimittel-Forschung 25: 1482–1491, 1975Google Scholar
  140. Seedat YK. Long-term treatment of hypertension with guanfacine (BS 100-141) alone and in combination therapy. Current Therapeutic Research 24: 288–298, 1978Google Scholar
  141. Spiegel R, Devos JE. Central effects of guanfacine and clonidine during wakefulness and sleep in healthy subjects. British Journal of Clinical Pharmacology 10 (Suppl. 1): 165–168, 1980Google Scholar
  142. Summers RJ, Jarrot B, Louis WJ. Selectivity of a series of clonidine-like drugs for α1and α2-adrenoceptors in rat brain. Neuroscience Letters 20: 347–350, 1980PubMedGoogle Scholar
  143. Szám I, Hollo J. Long-term antihypertensive therapy with guan-facine. International Journal of Clinical Pharmacology, Therapy and Toxicology 20: 388–392, 1982Google Scholar
  144. Szám I, Kállay K. Comparative study of two antihypertensive agents: guanfacine and guanethidine. British Journal of Clinical Pharmacology 10 (Suppl. 1): 85–87, 1980Google Scholar
  145. Thoolen MJMC, Hendriks JCA. Comparative studies on the cardiovascular withdrawal symptoms between clonidine, guanfacine and α-methyldopa in the conscious spontaneously hypertensive rat. Abstract no. 194. Archives of Pharmacology 319(Suppl.): R49, 1982Google Scholar
  146. Thoolen MJMC, Hendriks JCA, Timmermans PBMWM, van Zwieten PA. Precipitation by yohimbine of the withdrawal syndromes of clonidine, guanfacine, and methyldopa in the spontaneously hypertensive rat. Journal of Cardiovascular Pharmacology 5: 224–228, 1983PubMedGoogle Scholar
  147. Thoolen MJMC, Timmermans PBMWM, van Zwieten PA. Continuous infusion of guanfacine and clonidine and precipitation of their withdrawal syndromes in the rat. British Journal of Pharmacology 75 (Suppl.): 74p, 1982Google Scholar
  148. Thoolen MJMC, Timmermans PBMWM, van Zwieten PA. Guanfacine and clonidine: antihypertensive and withdrawal characteristics after continuous infusion and its interruption in the spontaneously hypertensive and normotensive rat. Naunyn-Schmiedeberg’s Archives of Pharmacology 319: 82–86, 1982PubMedGoogle Scholar
  149. Thoolen MJMC, Timmermans PBMWM, van Zwieten PA. Cardiovascular effects of withdrawal of some centrally acting antihypertensive drugs in the rat. British Journal of Clinical Pharmacology 15 (Suppl. 4): 491–505, 1983Google Scholar
  150. Timmermans PBMWM, Schoop AMC, van Zwieten PA. Binding characteristics of [3H] guanfacine to rat brain α-adrenoceptors. Biochemical Pharmacology 31: 899–905, 1982PubMedGoogle Scholar
  151. Velasco M, Urbina-Quintana A, Morillo J, Vizcarrondo H, Ramirez A, et al. Systemic and cardiac haemodynamic interactions between guanfacine and hydrallazine in hypertensive patients. European Journal of Clinical Pharmacology 27: 393–396, 1984PubMedGoogle Scholar
  152. Velly J. Effets de quatre hypotenseurs, la clonidine, la lofexidine, le BS 100-141 et l’ipro 4 sur le métabolisme de la noradrénaline centrale et cardiaque du rat. Journal de Pharmacologie 8: 351–360, 1977 auWaite R. Inhibition of sympathetic nerve activity, resulting from central alpha-adrenoceptor stimulation. In Milliez P, Sofar M (Eds) Recent advances in hypertension, Vol. II, pp. 27–31, Boehringer Ingelheim, 1975Google Scholar
  153. Weidinger G, Welzel D. Kombinationstherapie mit Guanfacin und Clopamid. Münchener Medizinische Wochenschrift 126: 776–780, 1984Google Scholar
  154. Weiss YA, Lavène DL, Safar ME, Simon AC, Loria Y, et al. Guanfacine kinetics in patients with hypertension. Clinical Pharmacology and Therapeutics 25: 283–293, 1979PubMedGoogle Scholar
  155. Westelinck K, Michotte Y. Low dose guanfacine once-a-day for the treatment of hypertension in general practice: a multi-centre pilot study. Current Medical Research and Opinion 7: 631–638, 1982Google Scholar
  156. Wetzels E, Raschig A, Kaiser HJ. Ein neues Antihypertensivum, angewendet unter Praxisbedingungen. Sonderdruck Medizinische Klinik 75: 688–692, 1980Google Scholar
  157. Wetzeis E, Weidinger G. Antihypertensive Wirksamkeit einer Guanfacin/Clopamid-Kombination. Münchener Medizinische Wochenschrift 124: 871–874, 1982Google Scholar
  158. Wever AMJ, van Brummelen P. The influence of guanfacine on blood pressure and lung function in hypertensive patients with chronic obstructive lung disease. British Journal of Clinical Pharmacology 15 (Suppl. 4): 521–523, 1983Google Scholar
  159. Wilson M, Haring O, Lewin A, Bedsole G, Stepansky W, et al. A comparison of guanfacine versusclonidine for efficacy, safety and the occurrence of the withdrawal syndrome in the step-2 treatment of mild to moderate essential hypertension. American Journal of Cardiology 57: in press, 1986Google Scholar
  160. Wing LMH, Reid JL, Hamilton CA, Sever PS, Davies DS, et al. Effects of clonidine on biochemical indices of sympathetic function and plasma renin activity in normotensive man. Clinical Science and Molecular Medicine 53: 45–53, 1977PubMedGoogle Scholar
  161. Zamboulis C, Reid JL. Effects of single and multiple doses of guanfacine in essential hypertension. Clinical Pharmacology and Therapeutics 28: 715–721, 1980PubMedGoogle Scholar
  162. Zamboulis C, Reid JL. Withdrawal of guanfacine after long-term treatment in essential hypertension. Observations on blood pressure and plasma and urinary noradrenaline. European Journal of Clinical Pharmacology 19: 19–24, 1981Google Scholar
  163. Zschiedrich H, Renschin G, Lüth JB, Philipp T, Distler A, et al. Veränderungen von Sympathikusaktivität und Blutdruckwirksamkeit von exogenem Noradrenalin unter pharmakologischer Blutdrucksenkung. Untersuchungen mit einem Diuretikum und einem Zentralen α-Rezeptorenstimulator bei Patienten mit essentieller Hypertonie. In Siegel L, Hüttig H (Eds) 88. Tagung der Deutschen Gesellschaft für Innere Medizin, Wiesbaden, 18–22 Apr 1982, pp. 139–140, Carl Ritter, Co., Wiesbaden, 1982Google Scholar
  164. van Zwieten PA. Pharmacology of centrally acting hypotensive drugs. British Journal of Clinical Pharmacology 10 (Suppl. 1): 135–205, 1980Google Scholar

Copyright information

© ADIS Press Limited 1986

Authors and Affiliations

  • Eugene M. Sorkin
    • 1
  • Rennie C. Heel
    • 1
  1. 1.ADIS Drug Information ServicesMairangi Bay, Auckland 10New Zealand

Personalised recommendations